This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Clover Biopharmaceuticals Crescita futura

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.

n/a

Tasso di crescita degli utili

190.4%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	40.0%
Tasso di crescita dei ricavi	47.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	27 Jul 2023

Nessun aggiornamento

Previsioni di crescita degli utili e dei ricavi

SHSC:2197 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	2,341	N/A	N/A	N/A	1
12/31/2024	3,071	N/A	N/A	N/A	2
12/31/2023	2,571	N/A	N/A	N/A	2
6/30/2023	0	-665	N/A	N/A	N/A
3/31/2023	0	-1,559	N/A	N/A	N/A
12/31/2022	N/A	-2,452	-1,796	-1,691	N/A
9/30/2022	N/A	-4,145	-1,461	-1,356	N/A
6/30/2022	N/A	-5,838	-1,125	-1,021	N/A
3/31/2022	N/A	-5,927	-1,062	-969	N/A
12/31/2021	N/A	-6,016	-998	-918	N/A
12/31/2020	N/A	-913	363	477	N/A

Guadagni vs tasso di risparmio: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (1.9%).

Guadagni vs Mercato: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market

Guadagni ad alta crescita: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: 2197's revenue (47.9% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).

Ricavi ad alta crescita: 2197's revenue (47.9% per year) is forecast to grow faster than 20% per year.

ROE futuro: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time